A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy

Takeuchi, Satoshi; Honma, Rio; Taguchi, Jun; Amano, Toraji; Shimizu, Yasushi; Kinoshita, Ichiro; Kubota, Kanako; Matsuno, Yoshihiro; Dosaka‐Akita, Hirotoshi

doi:10.1159/000328802

Cited by 7 publications

(3 citation statements)

References 10 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EP regimen may have been considered as one of the best choice for NEC so far, but unfortunately, the insurance system in Japan did not cover the regimen for NEC. Although modified FOLFOX6 plus bevacizumab was not commonly used for MANEC, some studies have reported administration of FOLFOX regimen to patients with MANEC and its effectiveness [12,13]. Additionally, at least 30% of the MANEC tumor comprises adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

Favorable response of colonic mixed adenoneuroendocrine carcinoma to streptozocin monotherapy

et al. 2017

View full text Add to dashboard Cite

Mixed adenoneuroendocrine carcinoma (MANEC) of the colon is rare and has a poor prognosis. Here, we report a case of MANEC in the ascending colon, in which streptozocin monotherapy achieved a partial response. A 36-year-old woman underwent right hemicolectomy for colonic polyposis, which included ascending colon cancer. Pathological examination revealed that some mucosal polyps were adenocarcinoma while one submucosal polyp was neuroendocrine carcinoma. Adjuvant chemotherapy was not administered, and 5 months after the operation, multiple liver metastases were identified. She was started on modified (5-FU, leucovorin, oxaliplatin) followed by XELOX (capecitabine, oxaliplatin) plus bevacizumab. Although these regimens helped achieve stable disease, computed tomography showed that the hepatic metastatic lesions had enlarged 4 months later. Subsequently, the regimen was changed to streptozocin monotherapy (1000 mg/m 2 , weekly). After 5 cycles, the regimen achieved partial response and was continued for a total of 17 courses without significant adverse events until progressive disease. As a third-line chemotherapy regimen, cisplatin plus etoposide (EP) was administered. The EP regimen reduced the size of the hepatic and ovarian metastatic lesions but severe neutropenia and anemia was observed. Amrubicin monotherapy was also administered as fourth-line chemotherapy but a good clinical response was not detected, and the patient died 20 months after the operation. Streptozocin monotherapy has the potential to be a therapeutic option for mixed adenoneuroendocrine carcinoma of the colon.

show abstract

Section: Discussionmentioning

confidence: 99%

Favorable response of colonic mixed adenoneuroendocrine carcinoma to streptozocin monotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…There are reports of clinical benefit when combined with existing chemotherapy treatments [148, 149]. …”

Section: Systemic Therapiesmentioning

confidence: 99%

“…Vascular endothelial growth factor (VEGF) is overexpressed in NETs and targeted by the ligand monoclonal antibody Bevacizumab [ 40 , 146 , 147 ]. There are reports of clinical benefit when combined with existing chemotherapy treatments [ 148 , 149 ].…”

Section: Systemic Therapiesmentioning

confidence: 99%

A Multimodal Approach to the Management of Neuroendocrine Tumour Liver Metastases

Basuroy

Srirajaskanthan

2012

International Journal of Hepatology

View full text Add to dashboard Cite

show abstract

Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41–BEVANEC randomized phase II study

Walter

Malka

Hentic

et al. 2018

Digestive and Liver Disease

View full text Add to dashboard Cite

A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy

Cited by 7 publications

References 10 publications

Favorable response of colonic mixed adenoneuroendocrine carcinoma to streptozocin monotherapy

Favorable response of colonic mixed adenoneuroendocrine carcinoma to streptozocin monotherapy

A Multimodal Approach to the Management of Neuroendocrine Tumour Liver Metastases

Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41–BEVANEC randomized phase II study

Contact Info

Product

Resources

About